Published in Trends Mol Med on January 28, 2010
The immunology of stroke: from mechanisms to translation. Nat Med (2011) 6.53
Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration. J Transl Med (2011) 1.47
Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol (2012) 1.28
Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J Clin Invest (2011) 1.24
Disease-causing mutations in genes of the complement system. Am J Hum Genet (2011) 1.24
Complement activation in the injured central nervous system: another dual-edged sword? J Neuroinflammation (2012) 1.11
Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration. Nat Commun (2013) 1.08
Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation (2012) 1.03
Innate immunity and neuroinflammation. Mediators Inflamm (2013) 0.90
Low ficolin-3 levels in early follow-up serum samples are associated with the severity and unfavorable outcome of acute ischemic stroke. J Neuroinflammation (2011) 0.88
Prion disease and the innate immune system. Viruses (2012) 0.86
Role of C/EBP-β, p38 MAPK, and MKK6 in IL-1β-mediated C3 gene regulation in astrocytes. J Cell Biochem (2011) 0.83
Dynamic control of the complement system by modulated expression of regulatory proteins. Lab Invest (2010) 0.80
No effect of ablation of surfactant protein-D on acute cerebral infarction in mice. J Neuroinflammation (2014) 0.79
Age-Related Macular Degeneration: A Disease of Systemic or Local Complement Dysregulation? J Clin Med (2014) 0.78
Improved fracture healing in patients with concomitant traumatic brain injury: proven or not? Mediators Inflamm (2015) 0.78
Ganglioside deficiency causes inflammation and neurodegeneration via the activation of complement system in the spinal cord. J Neuroinflammation (2014) 0.75
Low serum ficolin-3 levels are associated with severity and poor outcome in traumatic brain injury. J Neuroinflammation (2015) 0.75
Assessing candidate serum biomarkers for Alzheimer's disease: a longitudinal study. J Alzheimers Dis (2012) 0.75
Signaling pathways regulating neuron-glia interaction and their implications in Alzheimer's disease. J Neurochem (2015) 0.75
Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury , drive secondary injury by activating complement. J Neuroinflammation (2017) 0.75
Social controls on cell survival and cell death. Nature (1992) 9.81
The classical complement cascade mediates CNS synapse elimination. Cell (2007) 9.06
Programmed cell death in animal development. Cell (1997) 8.95
Apoptosis. Immunol Today (1993) 4.23
Apoptosis and caspases in neurodegenerative diseases. N Engl J Med (2003) 3.40
Cell death: apoptosis versus necrosis (review). Int J Oncol (2002) 2.20
p53 in neuronal apoptosis. Biochem Biophys Res Commun (2005) 1.85
Role of complement in neurodegeneration and neuroinflammation. Mol Immunol (2006) 1.73
Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J (2006) 1.70
Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease. J Neurochem (2008) 1.45
Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol (2000) 1.27
The role of the complement system in innate immunity. Immunol Res (2005) 1.19
Inflammatory signals induce neurotrophin expression in human microglial cells. J Neurochem (1998) 1.18
Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem (1999) 1.18
Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol (2001) 1.17
Complement activation in the human brain after traumatic head injury. J Neurotrauma (2001) 1.13
Complement activation in the central nervous system following blood-brain barrier damage in man. Ann Neurol (1996) 1.11
Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol Dis (1996) 1.10
Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport (2001) 1.06
Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J Immunol (1999) 1.06
The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. J Neuroimmunol (2000) 1.03
A neuronal C5a receptor and an associated apoptotic signal transduction pathway. J Physiol (1998) 1.03
C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J Immunol (2001) 1.03
Role of complement anaphylatoxin receptors (C3aR, C5aR) in the development of the rat cerebellum. Mol Immunol (2008) 1.02
Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. J Neuroinflammation (2008) 1.02
Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia (1999) 1.02
Oxidative stress in neurodegenerative diseases: therapeutic implications for superoxide dismutase mimetics. Expert Opin Biol Ther (2003) 1.01
Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice. J Neuroinflammation (2009) 1.00
The complement system in central nervous system diseases. Autoimmunity (2006) 1.00
Differential expression of individual complement regulators in the brain and choroid plexus. Lab Invest (1999) 0.99
C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. J Immunol (2006) 0.99
Characterization of C3a and C5a receptors in rat cerebellar granule neurons during maturation. Neuroprotective effect of C5a against apoptotic cell death. J Biol Chem (2004) 0.98
TNF-alpha-mediated expression of the receptor for anaphylatoxin C5a on neurons in experimental Listeria meningoencephalitis. J Immunol (1997) 0.94
NF-kappaB modulates lipopolysaccharide-induced microglial nerve growth factor expression. Glia (1998) 0.93
C3a expressed in the central nervous system protects against LPS-induced shock. Neurosci Lett (2005) 0.91
Interleukin-1beta and anaphylatoxins exert a synergistic effect on NGF expression by astrocytes. J Neuroinflammation (2006) 0.91
Sublytic complement attack exposes C-reactive protein binding sites on cell membranes. J Immunol (1994) 0.90
Kinetics of anaphylatoxin C5a receptor expression during experimental allergic encephalomyelitis. J Neuroimmunol (1998) 0.86
Complement and glutamate neurotoxicity. Genotypic influences of C5 in a mouse model of hippocampal neurodegeneration. Mol Chem Neuropathol (1997) 0.86
Role of mitochondrial proteins for neuronal cell death after focal cerebral ischemia. Acta Neurochir Suppl (2004) 0.83
Signaling through C5aR is not involved in basal neurogenesis. J Neurosci Res (2007) 0.82
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 4.21
Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. J Neurosurg (2011) 2.21
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A (2003) 2.05
Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet (2002) 1.67
Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A (2004) 1.63
Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol (2003) 1.63
Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci (2002) 1.58
Chiari I malformation as a cause of trigeminal neuralgia: case report. Neurosurgery (2008) 1.57
Increased generation of granule cells in adult Bcl-2-overexpressing mice: a role for cell death during continued hippocampal neurogenesis. Eur J Neurosci (2005) 1.53
Philanthropy funding for neurosurgery research and program development. Neurosurgery (2013) 1.40
Fundamental role of the Rip2/caspase-1 pathway in hypoxia and ischemia-induced neuronal cell death. Proc Natl Acad Sci U S A (2003) 1.40
Allele-specific silencing of mutant Huntington's disease gene. J Neurochem (2009) 1.35
Treatment of ruptured and unruptured cerebral aneurysms in the USA: a paradigm shift. J Neurointerv Surg (2011) 1.19
Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med (2004) 1.19
Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. J Neurosci (2008) 1.17
Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS. Mol Cell Neurosci (2002) 1.17
Huntingtin inhibits caspase-3 activation. EMBO J (2006) 1.17
Depletion of wild-type huntingtin in mouse models of neurologic diseases. J Neurochem (2003) 1.12
Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta (2005) 1.08
Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury. Stroke (2009) 1.08
Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet (2010) 1.06
Cytochrome C and caspase-9 expression in Huntington's disease. Neuromolecular Med (2002) 1.03
N-acetyl-serotonin offers neuroprotection through inhibiting mitochondrial death pathways and autophagic activation in experimental models of ischemic injury. J Neurosci (2014) 1.00
The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J Neurosci (2011) 0.96
Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol (2006) 0.96
Nortriptyline delays disease onset in models of chronic neurodegeneration. Eur J Neurosci (2007) 0.96
Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington's disease. J Neurochem (2003) 0.95
Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J Neurosci (2004) 0.94
Composite ganglioneuroma-paraganglioma of the filum terminale. J Neurosurg Spine (2010) 0.92
Nortriptyline protects mitochondria and reduces cerebral ischemia/hypoxia injury. Stroke (2008) 0.91
Increased stem cell proliferation in the spinal cord of adult amyotrophic lateral sclerosis transgenic mice. J Neurochem (2007) 0.89
Protective role of Cop in Rip2/caspase-1/caspase-4-mediated HeLa cell death. Biochim Biophys Acta (2006) 0.89
Dysregulation of receptor interacting protein-2 and caspase recruitment domain only protein mediates aberrant caspase-1 activation in Huntington's disease. J Neurosci (2005) 0.88
Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol Life Sci (2013) 0.88
The mitochondrial permeability transition as a target for neuroprotection. J Bioenerg Biomembr (2004) 0.87
Minocycline is protective in a mouse model of Huntington's disease. Ann Neurol (2003) 0.87
Dipyrone inhibits neuronal cell death and diminishes hypoxic/ischemic brain injury. Neurosurgery (2011) 0.87
Oxidative stress is associated with cell death, wall degradation, and increased risk of rupture of the intracranial aneurysm wall. Neurosurgery (2013) 0.87
Preliminary results of the ARUBA study. Neurosurgery (2013) 0.85
Intracellular signaling pathways and size, shape, and rupture history of human intracranial aneurysms. Neurosurgery (2012) 0.84
Promethazine: a novel application as a neuroprotectant that reduces ischemia-mediated injury by inhibiting mitochondrial dysfunction. Clin Neurosurg (2004) 0.83
Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis (2013) 0.83
Images in clinical medicine. Pneumocephalus associated with pneumosinus dilatans frontalis. N Engl J Med (2007) 0.81
Regeneration of neuromuscular synapses: action of microRNA-206. Neurosurgery (2010) 0.80
Bioengineering solutions for neural repair and recovery in stroke. Curr Opin Neurol (2013) 0.79
The experience of pain and the putamen: a new link found with functional MRI and diffusion tensor imaging. Neurosurgery (2011) 0.78
Inflammation triggered by traumatic brain injury may continue to harm the brain for a lifetime. Neurosurgery (2013) 0.78
Application of high-definition fiber tractography in the management of supratentorial cavernous malformations: a combined qualitative and quantitative approach. Neurosurgery (2014) 0.78
T-cell activation in ischemic stroke: a new therapeutic target for delayed infarct expansion? Neurosurgery (2009) 0.77
Pericytes as a therapeutic target in scar formation after spinal cord injury. Neurosurgery (2013) 0.77
Blocking TGF-β activity and associated inflammation may halt hydrocephalus. Neurosurgery (2013) 0.77
Angiogram-negative subarachnoid hemorrhage: relationship between bleeding pattern and clinical outcome. Neurocrit Care (2012) 0.76
What sequences on high-field MR best depict temporal resolution of experimental ICH and edema formation in mice? J Biomed Biotechnol (2012) 0.76
Intratumoral Clostridium novyi as a potential treatment for solid necrotic brain tumors. Neurosurgery (2014) 0.76
α-1 Adrenergic receptor signaling linked to memory dysfunction following brain trauma. Neurosurgery (2011) 0.76
Intraoperative awakening for vision examination during ophthalmic artery aneurysm clipping: technical case report. Neurosurgery (2005) 0.76
Parasellar arachnoid cyst presenting with a nonpupil sparing third nerve palsy mimicking a posterior communicating artery aneurysm in an adult. Surg Neurol Int (2013) 0.75
Response. J Neurosurg (2015) 0.75
A novel target for ischemic stroke therapy: pannexins. Neurosurgery (2012) 0.75
Stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med (2010) 0.75
Randomized-controlled trial of minocycline for spinal cord injury shows promise. Neurosurgery (2013) 0.75
Complete spinal cord injury: an indication for spinal cord stimulation? Neurosurgery (2014) 0.75
Scar in the injured spinal cord: the news is not all bad. Neurosurgery (2014) 0.75
Novel neurogenesis drugs uncovered from in vivo chemical library screen. Neurosurgery (2010) 0.75
Diffusion weighted imaging: what are we really seeing? Neurosurgery (2010) 0.75
Genomics of human glioblastoma multiforme: a glimpse of the future. Neurosurgery (2008) 0.75
Recovery of cortical control over locomotion after spinal cord injury. Neurosurgery (2012) 0.75
A brief history of early neuroanesthesia. Neurosurg Focus (2014) 0.75
In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma. Neurosurgery (2014) 0.75
Comparison of Computed Tomographic Angiography and Digital Subtraction Angiography in the Initial Management of Patients with Subarachnoid Hemorrhage 809. Neurosurgery (2006) 0.75
Targeted oncogenes create a new realistic mouse model of glioblastoma multiforme. Neurosurgery (2009) 0.75
Seizures and free radicals: the antioxidant may become the next anticonvulsant. Neurosurgery (2011) 0.75
Real-time multiphoton microscopy in moving animals: new frontier of functional imaging. Neurosurgery (2010) 0.75
A BigBrain for all…. Neurosurgery (2013) 0.75
Neuroprosthetic learning utilizes the same neural circuitry required for motor learning. Neurosurgery (2012) 0.75
Noninvasive monitoring of neural activity with bioluminescence. Neurosurgery (2010) 0.75
Neuronal transplants reconstitute complex neuronal circuitry and rescue phenotype. Neurosurgery (2012) 0.75
Molecular targets for neonatal communicating hydrocephalus, putting shunts out to pasture? Neurosurgery (2013) 0.75
324 Neurosurgical Cost Containment Via Improved Physician Awareness. Neurosurgery (2016) 0.75
Neuromodulation of the locus coeruleus: a key to controlling wakefulness. Neurosurgery (2011) 0.75
Battling brain diabetes: antioxidants may reduce cognitive deficits induced by cholesterol. Neurosurgery (2011) 0.75
Biopsy neuropathology of cerebral ischemia associated with a developmental venous anomaly. Clin Neurol Neurosurg (2012) 0.75
Transcranial focused ultrasound modulates the activity of primary somatosensory cortex in humans. Neurosurgery (2014) 0.75
Memory training unlocks brain plasticity in prodromal Alzheimer's disease. Neurosurgery (2011) 0.75
Connectivity features for identifying cognitive impairment in presymptomatic carotid stenosis. Neurosurgery (2014) 0.75
Neuromotor prosthetics: brain-computer interfaces, a step closer to benefitting paralyzed patients. Neurosurgery (2008) 0.75
Aneurysmal subarachnoid hemorrhage with concomitant posterior communicating artery fenestration. Int J Neurosci (2014) 0.75
Use of a simple internal fiducial as an adjunct to enhance intraoperative ultrasound-assisted guidance: technical note. Neurosurgery (2011) 0.75
Novel triple-modality molecular imaging approach holds promise for improving brain tumor resection. Neurosurgery (2012) 0.75
Harnessing the brain's tools for killing cancer cells could be a key to treating high-grade gliomas. Neurosurgery (2012) 0.75
Electrical stimulation of the thalamus modulates cortico-cortical signaling. Neurosurgery (2010) 0.75
Embolus extravasation: a new mechanism for microvascular recanalization? Neurosurgery (2010) 0.75
A novel vehicle for the delivery of exogenous neurotrophic factors in spinal cord injury. Neurosurgery (2015) 0.75